Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from NeoGenomics

It's Not Too Late to Jump on These Under-the-Radar Momentum Plays

These three stocks may fly under the radar, but their recent price increases could appeal to investors seeking a momentum play.

MarketBeat

NeoGenomics Is On The Upswing, Reversing A CEO-Tied Sell-Off, On Bullish Long-Term Guidance

NeoGenomics stock jumped Wednesday after the company issued a strong 2025 outlook. That partially reversed a recent selloff.

Investors Business Daily

NeoGenomics Earns Relative Strength Rating Upgrade; Hits Key Threshold

NeoGenomics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 80 to 83.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Stocks To Watch: NeoGenomics Sees RS Rating Jump To 81

NeoGenomics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 72 to 81.

Investors Business Daily

IBD Rating Upgrades: NeoGenomics Flashes Improved Price Strength

NeoGenomics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

NeoGenomics Shows Rising Relative Strength; Still Shy Of Key Threshold

NeoGenomics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

NeoGenomics Getting Closer To Key Technical Measure

NeoGenomics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

S&P 500 Misses Out On Record As Stock Market Fades Late; Small Caps On Pace For Record December

A pullback or moderation in the small-cap rally should come as no surprise.

Investors Business Daily

Investors Cash In On 12 'Triple Play' Stocks That Do No Wrong

Investors are worried that S&P 500 stocks will let them down. So why not focus on the handful that are delivering perfection?

Investors Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For August 26, 2022

Upgrades

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 22, 2022

Upgrades

Benzinga

Analyst Ratings for NeoGenomics

Over the past 3 months, 10 analysts have published their opinion on NeoGenomics (NASDAQ:NEO) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga

Analyst Ratings for NeoGenomics

Analysts have provided the following ratings for NeoGenomics (NASDAQ:NEO) within the last quarter:

Benzinga

NeoGenomics: Q1 Earnings Insights

NeoGenomics (NASDAQ:NEO) reported its Q1 earnings results on Wednesday, April 27, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

NeoGenomics Stock Gets Downgrade After CEO Resigns And Other Negative Updates

NeoGenomics, Inc.

Investors Business Daily

NeoGenomics Stock Tanks After CEO Exits Amid Sales, Profitability Maelstrom

NeoGenomics CEO Mark Mallon stepped down Tuesday and the company expects light first-quarter results, leading NEO stock to tank.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 29, 2022

Upgrades

Benzinga

Why NeoGenomics Stock Is Plunging Today

NeoGenomics Inc's (NASDAQ:NEO) CEO Mark Mallon will step down as CEO and member of the Board, effective immediately. The Board has retained Russell Reynolds to search for the Company's next CEO The Board has appointed current Chair Lynn Tetrault, Esq. as Executive Chair and established an Interim Office of the CEO. Read…

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

10 Biggest Price Target Changes For Tuesday

BTIG cut the price target on NeoGenomics, Inc. (NASDAQ: NEO) from $35 to $28. NeoGenomics shares fell 29.2% to $12.60 in pre-market trading.

Benzinga

Where NeoGenomics Stands With Analysts

Over the past 3 months, 8 analysts have published their opinion on NeoGenomics (NASDAQ:NEO) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga

The Daily Biotech Pulse: Sanofi-IGM Ink Antibody Drug Collaboration; NeoGenomics Sinks On CEO Departure, Q1 Warning; Decision Day For Akebia

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

NeoGenomics Earnings Perspective: Return On Capital Employed

NeoGenomics (NASDAQ:NEO) brought in sales totaling $125.73 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 105.22%, resulting in a loss of $41.76 million.

Benzinga

Recap: NeoGenomics Q4 Earnings

NeoGenomics (NASDAQ:NEO) reported its Q4 earnings results on Wednesday, February 23, 2022 at 08:00 AM. Here's what investors need to know about the announcement. Earnings NeoGenomics reported in-line EPS of $-0.14 versus an estimate of $-0.14.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.